← Back to blog

Regulatory Lab Panels: What Applies to Your Lab Orders in 2026

November 18, 2026
Regulatory Lab Panels: What Applies to Your Lab Orders in 2026

The rules behind a lab panel depend on how the test was built. A panel made from commercially manufactured tests sits under FDA device rules. A panel a laboratory designs and runs in-house is a laboratory-developed test (LDT), and its rules have changed twice since 2024. FDA's broad LDT rule was vacated by a federal court on March 31, 2025, and FDA then reverted its regulation text. For practices, facilities and trial sponsors, the working question is no longer "when does the FDA phaseout hit?" It is "can my lab show me how every panel it runs is validated, documented and reported?"

This guide explains what a regulated panel is, where the LDT rule stands, what still governs your orders, and what to ask a laboratory partner before you send specimens.

Kohealth Labs
Choose a Laboratory Partner for Clearer Results
KoHealth Labs provides clinical laboratory testing, molecular diagnostics, specimen management, and electronic results reporting for healthcare and research partners.
Visit

TL;DR

  • A panel is a bundle of tests. Each test is either a commercially manufactured in vitro diagnostic (IVD) or a laboratory-developed test (LDT), and the category decides which federal rules apply.
  • The FDA's May 2024 LDT final rule was vacated on March 31, 2025. On September 19, 2025, FDA reverted the regulation text to what it was before the rule.
  • Because that phaseout no longer applies, the practical evidence of quality for your orders is the lab's own documentation: validation records, specimen handling procedures, and clear result reporting.
  • Specimen handling is where many errors begin. Check condition on receipt, record it, store under defined conditions, and follow written retention and disposal procedures.
  • Practices and sponsors do best with a laboratory partner that answers compliance questions directly and delivers results in formats their systems and submissions can use.

What a "regulatory lab panel" means in practice

A lab panel is a group of tests ordered together: a lipid panel, a comprehensive metabolic panel, a respiratory pathogen PCR panel, a wellness bundle, or a biomarker set built for a study protocol. Regulation attaches to each test in the panel, not to the word "panel."

A peer-reviewed review in the journal literature divides clinical laboratory tests into two groups. The first is commercially manufactured IVDs, such as the comprehensive metabolic panel and complete blood count. The second is LDTs, which include tests developed in-house for clinical use. Most clinical tests historically fall into the first group.

The FDA defines an LDT as an IVD intended for clinical use that is designed, manufactured and used within a single CLIA-certified laboratory meeting high-complexity requirements. An IVD, in plain terms, is a test that examines a human specimen such as blood, saliva or tissue to diagnose a condition, monitor it, or guide treatment. CLIA, the Clinical Laboratory Improvement Amendments, is the federal program that certifies laboratories that test human specimens.

The NIH SEED Regulatory Knowledge Guide adds three points that matter when you buy testing:

  • A test designed in an academic research lab but performed in a CLIA-certified clinical lab is not an LDT, even on the same campus.
  • Under CLIA, any LDT that modifies an FDA-approved IVD is a high-complexity test and must run in a high-complexity CLIA-certified lab.
  • A test designed or manufactured wholly or partly outside the lab that offers it is not an LDT. If part of an LDT's intellectual property is sold or licensed to another lab to perform, the test needs FDA clearance or approval.

So when someone says a panel is "regulated," ask which tests inside it are manufactured IVDs, which are LDTs, and under which CLIA certificate they run.

Where the FDA's LDT rule stands today

The timeline is short, and it is the most-searched part of this topic.

DateWhat happened
May 6, 2024FDA published a final rule amending 21 CFR 809.3(a) to state that IVDs are devices, including when offered as LDTs, with a four-year, five-stage phaseout of general enforcement discretion
March 31, 2025A federal district court in the Eastern District of Texas, in American Clinical Laboratory Association v. FDA, vacated the rule in its entirety and remanded it to the HHS Secretary
September 19, 2025FDA issued a final rule reverting 21 CFR 809.3(a) to the text that existed before the May 2024 rule

The 2024 rule would have phased in adverse event reporting and complaint files first, then establishment registration, device listing and labeling, then full quality system requirements, and finally premarket review for high-risk and then moderate- and low-risk LDTs. Targeted exemptions were planned for categories such as 1976-type LDTs, certain HLA transplantation tests, forensic tests, and tests approved by the New York State clinical laboratory program. Because the court vacated the rule, those stages and exemptions are not in force. FDA treated its September 2025 reversion as a ministerial step: once the court had vacated the rule, removing the added words from the regulation imposed no new requirements.

Two cautions follow. First, this is a moving area. Congress has introduced LDT legislation several times without enacting it, and the NIH SEED guide describes LDT regulation as complex and evolving. Treat any single article, including this one, as a snapshot and check FDA's Laboratory Developed Tests page for the current status. Second, a rule vacated is not a laboratory with nothing to prove. Your clinical, contractual and (for trials) submission obligations did not go away.

For legal questions about how a specific test is classified, speak with regulatory counsel. For questions about how your orders are run, reported and documented, speak with your laboratory.

What still governs the panels you order

CLIA certification

CLIA remains the baseline for any lab reporting patient results. High-complexity testing, which includes modified FDA-approved tests and in-house molecular methods, has to be run in a lab certified for high-complexity work. When you add a lab to your practice or your study, ask for its CLIA certificate type and which of its panels are manufactured IVDs and which are developed in-house.

Framed CLIA certificate in a clinical laboratory

FDA device rules for manufactured tests

For commercially manufactured IVDs, FDA's device requirements continue to apply to the manufacturer. Those requirements include adverse event reporting, registration, listing, labeling, investigational use rules, quality systems and premarket review. Your lab's job is to use these tests as intended, or to document and validate any modification. The quality-system habits behind those requirements are still worth looking for. One example is a documented process for corrective action and a CAPA effectiveness check, which confirms that a fix actually stopped a problem from recurring.

ISO 17025 is not a clinical standard

People often ask which labs are ISO 17025 accredited. ISO/IEC 17025 is the standard for testing and calibration laboratory competence. The Eurachem guide on accreditation describes it as applied to analytical laboratories such as microbiological ones. It is not what governs clinical LDTs in the United States, which fall under CLIA and FDA IVD oversight. Useful for handling discipline, but not a substitute for the CLIA question.

Research and trial data

If the panel feeds a study, the lab's regulatory story extends to the data. Electronic records and signatures in FDA-regulated studies raise questions about audit trails and traceability. Our guide to Part 11 lab data walks through what counts and how to prove it, and what a structured diagnostic data regulatory submission requires covers how results should be organized for review. If you are weighing how to run research testing without a long build-out, see how to avoid six-month CLIA buildouts.

Five specimen practices that protect every panel

A validated assay cannot rescue a compromised specimen. The Eurachem guide lists core practices for handling test items. They come from ISO 17025 rather than from clinical rules, but they describe the discipline that any lab reading your specimens should follow:

  1. Check and record condition on receipt. Temperature, packaging and labeling are noted when the specimen arrives.
  2. Consult before testing or rejecting. If a specimen is insufficient or in poor condition, the lab contacts the submitter and records what it found.
  3. Store under defined, recorded conditions. Specimens awaiting testing are held in a way that minimizes change.
  4. Follow written retention and disposal procedures. Nothing is kept or discarded ad hoc.
  5. Handle hazardous or heavily contaminated specimens with care. The aim is to prevent contamination from spreading.

For a practice, practices 1 and 2 translate into a simple expectation: your lab should tell you the same day when a specimen arrives in poor condition, and should not quietly run it. For a CRO or sponsor, they are the first line of the chain of custody your monitors and auditors will ask about.

How to vet a lab partner's compliance: a practical checklist

Use these questions whether you run a three-physician family practice, a skilled nursing facility, a federally qualified health center or a Phase II study.

Certification and scope

  • Which CLIA certificate does the lab hold, and which of its panels are manufactured IVDs and which are in-house?
  • Does the lab modify any manufactured tests? If so, where is the validation summary?

Documentation

  • Can the lab provide the labeling or summary document that describes each in-house test's intended use and performance? FDA notes that its labeling regulation for IVDs, 21 CFR 809.10(b), does not require a package insert, and that most laboratory manufacturers have used a summary document as the primary labeling.
  • How does the lab record and resolve complaints and corrective actions?

Specimen logistics

  • Who handles pickup, and how is condition on receipt recorded?
  • What happens when a specimen is compromised, and how fast do you hear about it?

Results and data

  • Can results arrive through your EHR or EMR, or through a provider portal, in a consistent format?
  • For studies, are results delivered in analysis-ready, standards-aligned files? Our guide to eight steps to analysis-ready lab data covers what sponsors should expect.

Responsiveness

  • Who answers when a result needs clarification, and how long does it take?

The last question is the one most practices underweight. Compliance is partly paperwork and partly whether a human who understands your order answers the phone.

Matching panels to your setting

The regulatory questions look different depending on who is ordering.

  • Primary care, internal medicine and family practice: most orders are routine chemistry, lipid and hematology panels built on manufactured IVDs. Your priorities are turnaround, clean specimen pickup and results flowing into your record system.
  • Urgent care and pediatrics: speed and clear communication on infectious disease and respiratory panels, including molecular testing, matter most.
  • Women's health, men's health, endocrinology, HRT and weight loss clinics: hormone and metabolic panels are ordered repeatedly, so consistency in how results are reported over time is the compliance advantage.
  • Skilled nursing, assisted living and home health: specimen collection at the point of care is the weak point, so mobile phlebotomy and scheduled courier pickup determine specimen quality.
  • CROs, sponsors and research institutions: central laboratory work must align panels to the protocol, keep specimen chain of custody, and deliver data in formats that support submissions.

What we offer

KoHealth Labs is a diagnostic laboratory and clinical research partner serving physicians, practices, healthcare facilities, pharmaceutical companies and CROs. Our services include clinical laboratory testing, molecular and PCR diagnostics, chemistry, microbiology, pathology support, specimen pickup and transportation, mobile phlebotomy, electronic results reporting, and LIS integration, along with EMR integration, provider portal access and dedicated onboarding and training. For studies, we provide bundled lab and imaging data, with regulatory-aligned data delivery and AI-driven analysis-ready data bundles.

You can use us as your primary laboratory or as an additional resource for specialized testing. Browse what we test, see our PCR testing for clinics, or read about clinical trial laboratory services.

Kohealth Labs

To talk through your panels, your systems and your specimen logistics, start at kohealthlabs.com.

Our perspective

We hear the same worry from practice managers and study directors: the rules around laboratory tests keep shifting, and no one has time to track them. The 2025 court decision on the LDT rule shows why. A rule can arrive, phase in on paper and be set aside within a year. What does not change is what your patients and your protocol need: a result that is accurate, documented and in your hands quickly.

That is why we focus on the parts of the work you can see and measure. We prioritize direct communication, fast turnaround and customized laboratory solutions, rather than the impersonal service providers can experience with large national laboratories. We connect with your EHR, EMR or LIS so results arrive where you work. We handle pickup and mobile phlebotomy so specimens reach us in good condition. For research, we deliver data aligned with regulatory expectations, so your team spends its time on the study and not on reformatting files.

Regulation will keep evolving. A laboratory partner who answers questions plainly, explains how each panel is run and adapts to your setting makes that change far easier to manage. That is the partnership we aim to be.

Kohealth Labs

FAQ

Which laboratories are exempt from federal laboratory regulations?

None are exempt from CLIA if they report human test results for patient care, though CLIA sets different requirements for waived, moderate and high-complexity testing. Under the 2024 LDT rule, FDA had planned targeted enforcement discretion for categories such as 1976-type LDTs, forensic tests and some government-run lab tests, but that rule was vacated in 2025. Ask regulatory counsel how a specific test is classified.

What does LDT mean?

LDT stands for laboratory-developed test. It is an in vitro diagnostic that is designed, manufactured and used within a single CLIA-certified laboratory. It is different from a commercially manufactured test kit, which is made by a manufacturer and used in many labs.

Is the FDA's LDT rule in effect?

No. A federal district court vacated the May 2024 final rule on March 31, 2025, and FDA reverted its regulation text on September 19, 2025. Check FDA's Laboratory Developed Tests page for the latest status, because the legal picture can change.

Does ISO 17025 accreditation apply to clinical lab panels?

ISO/IEC 17025 addresses competence of testing and calibration laboratories and is used for analytical labs. In the United States, clinical LDTs are governed by CLIA certification and FDA oversight of IVDs, so ISO 17025 does not replace the CLIA question when you choose a lab for patient testing.

Sources

For more information about our diagnostic testing, clinical research laboratory services, or partnership opportunities, visit https://kohealthlabs.com or contact KoHealth Labs at (469) 792-8439 and ask for Amy Patterson.